Rheumatology, Osteoarthritis, Extracellular Matrix Research
12. Dec 2017
Sprifermin (rhFGF18) Modulates Extracellular Matrix Turnover in Cartilage Explants ex vivo
ABSTRACT
Background: Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellul…
Read the publication
Journal:
Authors:
- Reker D,
- Kjelgaard-Petersen CF,
- Siebuhr AS,
- Michaelis M,
- Gigout A,
- Karsdal MA,
- Ladel C,
- Bay-Jensen AC,
Rheumatology, Osteoarthritis
1. Nov 2017
Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix
ABSTRACT
Objective: Fibroblast growth factor (FGF) 18 has been shown to increase cartilage volume when injected intra-articularly in animal models of osteoarthritis (OA) and in patients with knee OA (during clinical development of the recombinant human FGF18, sprifermin). However, the exact nature …
Read the publication
Journal:
Authors:
- Gigout A,
- Guehring H,
- Froemel D,
- Meurer A,
- Ladel C,
- Reker D,
- Bay-Jensen AC,
- Karsdal MA,
- Lindemann S,